跳至主要内容
临床试验/JPRN-UMIN000009750
JPRN-UMIN000009750已完成2 期

Phase II study of VCD therapy in patients with newly diagnosed, transplantation-eligible symptomatic multiple myeloma. - Shimousa MM-01 VCD study

Shimousa blood study group0 个研究点目标入组 30 人开始时间: 2013年1月15日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Non-secretory MM and plasmacell leukemia. 2. Patients with HIV antibody positive, HBs antigen posiive or HCV antibody positive 3. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 4. Patients with a history of active malignancy during the past 5 years. 5. Patients with psychiatric disorders such as schizophrenia etc. 6. Pregnant women, pre-menopausal women, and lactating women. 7. Patient was suspected pneumonia (Interstitial pneumonia). 8. Those who are considered as inappropriate to register by attending physicians.

研究者

发起方
Shimousa blood study group

相似试验

Phase II study of VCD therapy in patients with newly... | 临床试验